secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001178913-25-003385
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics enters ATM equity facility for up to $13.17M via H.C. Wainwright
--------------------------------------------------------------------------------

- At-the-market offering agreement with H.C. Wainwright to sell up to $13.17M of ordinary shares.
- Wainwright to receive 3% commission on gross proceeds; sales may occur via Nasdaq Capital Market.
- Offering terminates upon sale of all shares or earlier termination by either party.
- Company not obligated to sell any shares; sales subject to effectiveness of registration statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003385/0001178913-25-003385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003385/zk2533809.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer